Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Financial Results:
Granules India Ltd reported Revenues for Q3FY25 of ₹1,138.00 Crores down from ₹1,156.00 Crore year on year, a fall of 1.56%.
Total Expenses for Q3FY25 of ₹991.00 Crores up from ₹986.00 Crores year on year, a rise of 0.51%.
Consolidated Net Profit of ₹118.00 Crores down 6.35% from ₹126.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.85, down 6.37% from ₹5.18 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
